Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module - 7 Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2016
At a glance
- Drugs Ceritinib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Acronyms SIGNATURE
- Sponsors Novartis
- 27 Nov 2016 Status changed from recruiting to completed.
- 20 Sep 2016 Planned End Date changed from 1 Sep 2018 to 1 Mar 2018.
- 20 Sep 2016 Planned primary completion date changed from 1 Sep 2018 to 1 Mar 2018.